Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of a 21-valent pneumococcal conjugate vaccine in healthy infants
NL-OMON59124Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of PCV21 and 15-valent pneumococcal conjugate vaccine in pneumococcal disease (2 arms), sponsored by Sanofi. Primary endpoints: Seroresponse rate for PCV21 and 15vPCV serotypes and IgG concentration for PCV21 and 15vPCV serotypes. Started May 2025; status: completed.
02
Drugs
PCV2115-valent pneumococcal conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NL-OMON59124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59124.